Riluzole API

Name	Riluzole
Chinese name	利鲁唑
Cas Number	1744-22-5
Source	India
Qualifications	USDMF/-/-/-/-

Riluzole was the first drug approved by the FDA for the treatment of ALS and was approved for marketing in December 1995. So far, 3 drugs have been approved by the FDA for the treatment of ALS, including Rilutek (riluzole tablets), Tiglutik (riluzole suspension), and Radicava (edaravone, edaravone intravenous injection), but these drugs None of them can completely cure, stop or reverse the process of ALS disease, but can help relieve specific symptoms and slow down the progression of the disease. Riluzole exhibits its neuroprotective effects by inhibiting the release of neurotransmitters (glutamate and aspartic acid) in the brain, inhibiting the activity of excitatory amino acids and stabilizing the inactivation state of voltage-dependent sodium channels. Cell models have proved that riluzole can reduce the toxic effects of excitatory transmitters and increase the survival rate of cells.

Hot Tags: riluzole api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Bemeprost API, Deoxycholic Acid API, Lercanidipine Hydrochloride API, Cinacalcet Hydrochloride API, Ulipristal Acetate API, Vinpocetine API

• Previous: Torasemide API
• Next: Ferric Carboxymaltose API